You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood conditions

Eltrombopag for treating chronic immune thrombocytopenia

  • Technology appraisal guidance
  • Reference number: TA293
  • Published:  24 July 2013
  • Last updated:  26 October 2018
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Research recommendations coming out of this guidance

  • NICE recommends that research should be carried out to directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice.

  • NICE recommends research generating and analysing observational data including, but not limited to, the existing UK ITP Registry, which collects data on the long-term outcomes of patients treated with eltrombopag and romiplostim.

Back to top